AR055177A1 - Compuestos heterociclicos fusionados utiles como moduladores de cinasa - Google Patents
Compuestos heterociclicos fusionados utiles como moduladores de cinasaInfo
- Publication number
- AR055177A1 AR055177A1 ARP060104153A ARP060104153A AR055177A1 AR 055177 A1 AR055177 A1 AR 055177A1 AR P060104153 A ARP060104153 A AR P060104153A AR P060104153 A ARP060104153 A AR P060104153A AR 055177 A1 AR055177 A1 AR 055177A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- alkenyl
- alkynyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
Abstract
Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) o un enantiomero o una sal farmacéuticamente aceptable, del mismo, en donde: uno de E o F es N, y el otro de E o F es C; X es NR4R5; Z es N o CR3, con la condicion de que si E es N entonces Z es N; Y se selecciona de H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, halogeno, nitro, ciano, SR8, S(O)pR8, OR8, NR6R7, CO2R8, C(=O)R8, O-C(=O)R8, C(=O)NR8R9, cicloalquilo, cicloalquenilo, cicloalquinilo, heterociclo, arilo, y heteroarilo, con la condicion de que si Y es H entonces R4 es fenilo sustituido con un grupo carboxamido; R1 y R2 son independientemente seleccionados de (i) H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, halogeno, nitro, ciano, SR10, OR10, NR10R11, NR10C(=O) R11, CO2R10, C(=O)R10, -O-C(=O)R10, C(=O)NR10R11, cicloalquilo, heterociclo, arilo, y heteroarilo; o (ii) R1 se toma junto con R2 y los átomos en el anillo al cual se enlazan forman un cicloalquilo, arilo, heteroarilo, o cicloheteroalquilo fusionado de 5, 6 o 7 miembros; R3 se selecciona de H, halogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, nitro, ciano, SR13, OR13, NR13R14, NR13C(=O)R14, CO2R13, C(=O)R13, -O-C(=O)R13, C(=O)NR13R14, cicloalquilo, heterociclo, arilo, y heteroarilo; R4, R5, R6 y R7 son independientemente seleccionados de H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, OR15, SR15, C(= O)R15, CO2R15, C(=O)NR15R16, C(W)OR16, S(O)pR17, SO2NR15R16, cicloalquilo, heterociclo, arilo, y heteroarilo; o (ii) R4 se toma junto con R5 y el átomo de N al cual ambos se enlazan y/o R6 se toma junto con R7 y el átomo de N al cual ambos se enlaza para formar un anillo heteroarilo o heterociclo; R8, R9, R10, R11, R13, R14, R15 y R16, cada que se presentan, son independientemente seleccionados de (i) H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, cicloalquilo, arilo, heteroarilo, y heterociclo; o (ii) junto con el átomo de N al cual se enlaza, R8 se toma junto con R9, y/o R10 se toma junto con R11, y/o R13 se toma junto con R14, y/o R15 se toma junto con R16 para formar un anillo heteroarilo o heterociclo; R12, R17, y R18 cada que se presentan son independientemente seleccionados de alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, cicloalquilo, arilo, heteroarilo, y heterociclo; W cada que se presenta es O, S, N, CN o NH; y p es 1 o 2; con las siguientes condiciones: (1) si E es C, F es N y Z es CR3, y X es NH(Me), NH(Me)2, NH(fenilo no sustituido), o NHNH2, entonces Y es diferente a H o halogeno; y (2) si E es N, F es C, Z es N, e Y es NR6R7; (a) entonces X es diferente a NH(alquilo C1-4), N(alquilo C1-4), NH(alquenilo C1-4), NH(-CH2-furilo), NHNH2, NH(Cmetoxialquileno), y NHAc; (b) y si X es NH(- CH2-(sustituido o no sustituido)piridilo) o NH(-CH2-(sustituido o no sustituido)fenilo), entonces Y es diferente a compuesto de formula (2), NH(piperidina sustituido), o NH(-CH2-piridina); (c) y si X es NH(ciclopentilo), entonces Y es diferente a NH(ciclopentilo); (d) y si X es N(CH3) (fenilo sustituido), o N(CH3)(piridilo), entonces Y es diferente a compuesto de formula (2), o (e) y si X es NH(fenilo sustituido), entonces Y es diferente a compuesto de formula (3).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71951905P | 2005-09-22 | 2005-09-22 | |
| US11/524,996 US20070078136A1 (en) | 2005-09-22 | 2006-09-21 | Fused heterocyclic compounds useful as kinase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055177A1 true AR055177A1 (es) | 2007-08-08 |
Family
ID=37716206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104153A AR055177A1 (es) | 2005-09-22 | 2006-09-25 | Compuestos heterociclicos fusionados utiles como moduladores de cinasa |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20070078136A1 (es) |
| EP (1) | EP1928879B1 (es) |
| JP (1) | JP5241498B2 (es) |
| KR (2) | KR101399766B1 (es) |
| AR (1) | AR055177A1 (es) |
| AU (1) | AU2006295439B2 (es) |
| BR (1) | BRPI0616393B8 (es) |
| CA (1) | CA2623369C (es) |
| CY (1) | CY1114001T1 (es) |
| DK (1) | DK1928879T3 (es) |
| EA (1) | EA017632B1 (es) |
| ES (1) | ES2402664T3 (es) |
| GE (1) | GEP20104943B (es) |
| HR (1) | HRP20130155T1 (es) |
| IL (1) | IL190280A (es) |
| NO (1) | NO20081231L (es) |
| NZ (1) | NZ566663A (es) |
| PE (1) | PE20070520A1 (es) |
| PH (1) | PH12013501329B1 (es) |
| PL (1) | PL1928879T3 (es) |
| PT (1) | PT1928879E (es) |
| SI (1) | SI1928879T1 (es) |
| TW (2) | TWI478925B (es) |
| WO (1) | WO2007038314A2 (es) |
Families Citing this family (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002261A1 (es) * | 2006-08-04 | 2008-05-02 | Takeda Pharmaceutical | Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. |
| WO2008116064A2 (en) | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| AR067326A1 (es) * | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| BRPI0813625A2 (pt) * | 2007-07-26 | 2014-12-23 | Novartis Ag | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 |
| KR20100097711A (ko) * | 2007-11-21 | 2010-09-03 | 디코드 제네틱스 이에이치에프 | 폐 및 심혈관 질환의 치료를 위한 치환된 벤조아졸 ｐｄｅ4 억제제 |
| US20090324569A1 (en) * | 2007-11-21 | 2009-12-31 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders |
| KR101608096B1 (ko) * | 2008-01-23 | 2016-03-31 | 브리스톨-마이어스 스큅 컴퍼니 | ４-피리디논 화합물 및 암을 위한 그의 용도 |
| US8389527B2 (en) * | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| UY31676A1 (es) | 2008-02-28 | 2009-09-30 | "derivados de 3-metil-imidiazo-[1,2-b]-piridazina" | |
| US8404694B2 (en) * | 2008-03-20 | 2013-03-26 | Amgen Inc. | Aurora kinase modulators and method of use |
| BRPI0912668A2 (pt) * | 2008-05-13 | 2016-01-26 | Irm Llc | composto e composições como inibidores de quinase |
| WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| NZ589622A (en) * | 2008-05-21 | 2012-10-26 | Incyte Corp | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| JP2011529073A (ja) * | 2008-07-24 | 2011-12-01 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ調節因子として有用な縮合ヘテロ環化合物 |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| WO2010027114A1 (en) * | 2008-09-05 | 2010-03-11 | Choongwae Pharma Corporation | Use of pyrazole-pyridine derivatives and its salts for treating or reventin osteoporosis |
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| ES2900243T3 (es) | 2008-10-22 | 2022-03-16 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa |
| WO2010068810A2 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| PA8854101A1 (es) * | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| SG171815A1 (en) | 2008-12-19 | 2011-07-28 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
| JP5578490B2 (ja) | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| ES2481715T3 (es) | 2009-02-06 | 2014-07-31 | Janssen Pharmaceuticals, Inc. | Compuestos heterocíclicos bicíclicos sustituidos novedosos como moduladores de gamma-secretasa |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| AU2010262036B2 (en) | 2009-05-07 | 2014-10-30 | Cellzome Limited | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
| WO2010144647A1 (en) | 2009-06-12 | 2010-12-16 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| BR112012000915A2 (pt) | 2009-07-15 | 2019-09-24 | Janssen Pharmaceuticals Inc | derivados de triazol e imidazol substituídos como moduladores de gama secretase. |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| KR101774035B1 (ko) | 2009-10-30 | 2017-09-01 | 얀센 파마슈티카 엔.브이. | 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도 |
| EP2518072A4 (en) | 2009-12-24 | 2014-06-04 | Ajinomoto Kk | IMIDAZOPYRIDAZINE COMPOUNDS |
| CA2784765A1 (en) | 2010-01-15 | 2011-07-21 | Janssen Pharmaceuticals, Inc. | Novel substituted bicyclic triazole derivatives as gamma secretase modulators |
| US9073927B2 (en) | 2010-01-22 | 2015-07-07 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Inhibitors of PI3 kinase |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| CN102971326A (zh) | 2010-04-28 | 2013-03-13 | 百时美施贵宝公司 | 咪唑并哒嗪化合物及其在癌症中的用途 |
| WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
| MX2012013467A (es) | 2010-05-20 | 2013-04-29 | Array Biopharma Inc | Compuestos macrociclicos como inhibidores de trk cinasa. |
| US8685969B2 (en) | 2010-06-16 | 2014-04-01 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| US8987273B2 (en) | 2010-07-28 | 2015-03-24 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-B]pyridazines |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| TWI541243B (zh) * | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US9266880B2 (en) | 2010-11-12 | 2016-02-23 | Bristol-Myers Squibb Company | Substituted azaindazole compounds |
| US20130303532A1 (en) | 2010-12-17 | 2013-11-14 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| CN103370322B (zh) | 2010-12-17 | 2016-02-10 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 |
| CA2821817A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CN103502225B (zh) | 2011-03-24 | 2015-11-25 | 杨森制药公司 | 作为γ分泌酶调节剂的经取代的三唑基哌嗪以及三唑基哌啶衍生物 |
| GB201108003D0 (en) | 2011-05-13 | 2011-06-29 | Materialise Dental Nv | Endodontic treatment simulation system |
| WO2012156367A1 (en) | 2011-05-17 | 2012-11-22 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines as mknk1 kinase inhibitors |
| EP2714692B1 (en) | 2011-06-01 | 2017-03-22 | Bayer Intellectual Property GmbH | Substituted aminoimidazopyridazines |
| WO2012175591A1 (en) | 2011-06-22 | 2012-12-27 | Bayer Intellectual Property Gmbh | Heterocyclyl aminoimidazopyridazines |
| US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
| AU2012285931B2 (en) | 2011-07-15 | 2017-01-12 | Cellzome Limited | Novel substituted indole derivatives as gamma secretase modulators |
| AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| US9320737B2 (en) | 2011-09-23 | 2016-04-26 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| EP2760870B1 (en) | 2011-09-27 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| BR112014008126A2 (pt) * | 2011-11-01 | 2017-04-18 | Hoffmann La Roche | composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção |
| WO2013104573A1 (en) | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Pyridazine amide compounds and their use as syk inhibitors |
| US8969565B2 (en) * | 2012-03-09 | 2015-03-03 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use |
| ES2605946T3 (es) | 2012-03-14 | 2017-03-17 | Bayer Intellectual Property Gmbh | Imidazopiridazinas sustituidas |
| KR102096625B1 (ko) | 2012-05-16 | 2020-04-03 | 얀센 파마슈티칼즈, 인코포레이티드 | (무엇보다도) 알츠하이머병의 치료에 유용한 치환 3,4-디하이드로-2h-피리도[1,2-a]피라진-1,6-디온 유도체 |
| JP6426603B2 (ja) | 2012-06-26 | 2018-11-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 神経障害または代謝障害の治療に使用するための、１−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］−キノキサリン化合物などのＰＤＥ２阻害剤とＰＤＥ１０阻害剤との組合せ |
| EP2869822B1 (en) | 2012-07-09 | 2016-09-14 | Janssen Pharmaceutica, N.V. | Inhibitors of phosphodiesterase 10 enzyme |
| TW201414737A (zh) | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| US9428511B2 (en) | 2012-09-06 | 2016-08-30 | Bristol-Myers Squibb Company | Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
| JP6377068B2 (ja) | 2012-11-16 | 2018-08-22 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
| KR102209418B1 (ko) | 2012-12-20 | 2021-01-29 | 얀센 파마슈티카 엔.브이. | 감마 세크레타제 조절 인자로서의 신규 삼환 3,4-디하이드로-2H-피리도[1,2-α]피라진-1,6-디온 유도체 |
| CN105073751B (zh) * | 2012-12-21 | 2018-11-30 | 百时美施贵宝公司 | 作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑 |
| CN104837844B (zh) | 2012-12-21 | 2017-08-29 | 百时美施贵宝公司 | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 |
| CA2891755C (en) | 2013-01-17 | 2021-10-26 | Janssen Pharmaceutica Nv | Substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| US9193736B2 (en) | 2013-06-11 | 2015-11-24 | Janssen Pharmaceutica, Nv | PDE 10a inhibitors for the treatment of type II diabetes |
| WO2014200885A1 (en) | 2013-06-11 | 2014-12-18 | Janssen Pharmaceutica Nv | PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES |
| JP2016526534A (ja) | 2013-06-11 | 2016-09-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換トリアゾロピリジンのプロドラッグ誘導体 |
| US9714234B2 (en) | 2013-06-25 | 2017-07-25 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds |
| AR096721A1 (es) | 2013-06-25 | 2016-01-27 | Bristol Myers Squibb Co | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos |
| US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| EP3080131B1 (en) | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| WO2015097121A1 (en) | 2013-12-23 | 2015-07-02 | Norgine B.V. | Compounds useful as ccr9 modulators |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| TW201613927A (en) | 2014-09-01 | 2016-04-16 | Bayer Pharma AG | Method for preparation of substituted imidazopyridazines |
| CA2965517C (en) | 2014-10-24 | 2023-05-02 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhibitors |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| KR101635173B1 (ko) | 2014-12-03 | 2016-06-30 | 충남직물공업협동조합 | 디지털프린팅 날염 친환경 자카드직물의 제조방법 및 그 직물 |
| ES2761051T3 (es) | 2014-12-19 | 2020-05-18 | Janssen Pharmaceutica Nv | Derivados de imidazopiridazina como inhibidores de PI3Kbeta |
| EP3233839B1 (en) | 2014-12-19 | 2019-09-25 | Janssen Pharmaceutica NV | Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors |
| WO2016142855A2 (en) | 2015-03-09 | 2016-09-15 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
| TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| US20170174671A1 (en) | 2015-12-17 | 2017-06-22 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SI3394033T1 (sl) | 2015-12-22 | 2021-03-31 | Incyte Corporation | Heterociklične spojine kot imunomodulatorji |
| HUE068971T2 (hu) | 2016-04-04 | 2025-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| PT3800189T (pt) | 2016-05-18 | 2023-07-27 | Array Biopharma Inc | Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida |
| MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
| WO2017210399A1 (en) * | 2016-06-02 | 2017-12-07 | Celgene Corporation | Animal and human anti-malarial agents |
| ES2927984T3 (es) | 2016-06-20 | 2022-11-14 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| KR102611856B1 (ko) * | 2016-11-17 | 2023-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 이미다조피리다진 조정제 |
| EP3554257B1 (en) | 2016-12-15 | 2023-07-12 | Société des Produits Nestlé S.A. | Compositions and methods that modulate white blood cells or neutrophils in a companion animal |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| MX391981B (es) | 2016-12-22 | 2025-03-21 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores. |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JP7200126B2 (ja) | 2017-04-05 | 2023-01-06 | キュロヴィル・アクチボラグ | 療法において有用なヘテロ芳香族化合物 |
| EP3612030B1 (en) * | 2017-04-21 | 2025-12-24 | Ikena Oncology, Inc. | Indole ahr inhibitors and uses thereof |
| ES2994013T3 (en) * | 2017-07-28 | 2025-01-15 | Takeda Pharmaceuticals Co | Tyk2 inhibitors and uses thereof |
| WO2019169249A1 (en) * | 2018-03-01 | 2019-09-06 | The Johns Hopkins University | INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| PL3790877T3 (pl) | 2018-05-11 | 2023-06-12 | Incyte Corporation | Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1 |
| US12357631B2 (en) | 2018-07-27 | 2025-07-15 | Cocrystal Pharma, Inc. | Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication |
| AU2020212001A1 (en) | 2019-01-23 | 2021-07-22 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| EP3935058B1 (en) * | 2019-03-05 | 2024-08-21 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| AU2020278566A1 (en) * | 2019-05-17 | 2021-12-23 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| IL291471B2 (en) | 2019-09-30 | 2025-04-01 | Incyte Corp | Pyrimido[3,2–D]pyrimidine compounds as immunomodulators |
| CN114829366A (zh) | 2019-11-11 | 2022-07-29 | 因赛特公司 | Pd-1/pd-l1抑制剂的盐及结晶形式 |
| CA3181162A1 (en) | 2020-06-05 | 2021-12-09 | Stephen W. Kaldor | Inhibitors of fibroblast growth factor receptor kinases |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| CN117355533A (zh) * | 2021-06-22 | 2024-01-05 | 株式会社Lg化学 | 作为蛋白激酶抑制剂的新型化合物 |
| EP4268824A1 (en) * | 2022-04-26 | 2023-11-01 | Manros Therapeutics | Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament |
| WO2025199359A1 (en) * | 2024-03-21 | 2025-09-25 | The Translational Genomics Research Institute | Methods of modulating cdk7 and flt3 using fused bicyclic compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166851A (en) | 1977-05-16 | 1979-09-04 | Merck & Co., Inc. | Certain imidazo(1,2a)pyridine derivatives |
| CH635587A5 (fr) * | 1978-01-09 | 1983-04-15 | Aron Sa | Derives amines de pyrazolo (1,5-a) s.triazine, therapeutiquement actifs et leurs procedes de preparation. |
| FR2619818B1 (fr) * | 1987-09-01 | 1990-01-12 | Sanofi Sa | Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US5260285A (en) | 1990-12-07 | 1993-11-09 | Merck & Co., Inc. | Substituted imidazopyridazines as angiotensin II antagonists |
| DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
| CN1227554A (zh) | 1996-08-28 | 1999-09-01 | 辉瑞大药厂 | 取代的6,5－杂二环衍生物 |
| AU2002225096B8 (en) * | 2000-12-20 | 2006-07-27 | Ipsen Pharma S.A.S. | Cyclin-dependent kinase (CDK) and glycogen synthase kinase-3 (GSK-3) inhibitors |
| FR2850653A1 (fr) * | 2003-02-04 | 2004-08-06 | Univ Pasteur | Derives de pyrazolotriazine, procede de preparation et utilisations |
| WO2004076458A1 (en) * | 2003-02-28 | 2004-09-10 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyrimidine derivatives |
| DE10356579A1 (de) * | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
| TW200536536A (en) | 2004-02-25 | 2005-11-16 | Schering Corp | Pyrazolotriazines as kinase inhibitors |
| US7537840B2 (en) * | 2004-08-05 | 2009-05-26 | H.B. Licensing & Financing, Inc. | Polyamide adhesive and articles including the same |
| EP1879896A1 (en) * | 2005-04-05 | 2008-01-23 | Eli Lilly And Company | Imidazopyridazine compounds |
-
2006
- 2006-09-21 US US11/524,996 patent/US20070078136A1/en not_active Abandoned
- 2006-09-22 WO PCT/US2006/037056 patent/WO2007038314A2/en not_active Ceased
- 2006-09-22 KR KR1020087009516A patent/KR101399766B1/ko not_active Expired - Fee Related
- 2006-09-22 TW TW102124973A patent/TWI478925B/zh not_active IP Right Cessation
- 2006-09-22 DK DK06825074.5T patent/DK1928879T3/da active
- 2006-09-22 JP JP2008532430A patent/JP5241498B2/ja not_active Expired - Fee Related
- 2006-09-22 PL PL06825074T patent/PL1928879T3/pl unknown
- 2006-09-22 TW TW095135141A patent/TWI441825B/zh not_active IP Right Cessation
- 2006-09-22 NZ NZ566663A patent/NZ566663A/en not_active IP Right Cessation
- 2006-09-22 HR HRP20130155TT patent/HRP20130155T1/hr unknown
- 2006-09-22 EP EP06825074A patent/EP1928879B1/en active Active
- 2006-09-22 KR KR1020147007661A patent/KR20140058645A/ko not_active Withdrawn
- 2006-09-22 EA EA200800873A patent/EA017632B1/ru not_active IP Right Cessation
- 2006-09-22 BR BRPI0616393A patent/BRPI0616393B8/pt not_active IP Right Cessation
- 2006-09-22 GE GEAP200610649A patent/GEP20104943B/en unknown
- 2006-09-22 AU AU2006295439A patent/AU2006295439B2/en not_active Ceased
- 2006-09-22 PE PE2006001149A patent/PE20070520A1/es active IP Right Grant
- 2006-09-22 PT PT68250745T patent/PT1928879E/pt unknown
- 2006-09-22 ES ES06825074T patent/ES2402664T3/es active Active
- 2006-09-22 SI SI200631578T patent/SI1928879T1/sl unknown
- 2006-09-22 CA CA2623369A patent/CA2623369C/en active Active
- 2006-09-25 AR ARP060104153A patent/AR055177A1/es active IP Right Grant
-
2008
- 2008-03-10 NO NO20081231A patent/NO20081231L/no not_active Application Discontinuation
- 2008-03-18 IL IL190280A patent/IL190280A/en active IP Right Grant
-
2013
- 2013-05-09 CY CY20131100374T patent/CY1114001T1/el unknown
- 2013-06-21 PH PH12013501329A patent/PH12013501329B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055177A1 (es) | Compuestos heterociclicos fusionados utiles como moduladores de cinasa | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
| AR076067A1 (es) | Composiciones y metodos para modular la senda de senalizacion de wnt | |
| AR050966A1 (es) | Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms) | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| AR043055A1 (es) | Derivados de 1-(4-benzil-piperazin-1-il)-3- fenil-propenona | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| CO5721002A2 (es) | Derivados de acido 3-(4-benciloxifenil) propanoico | |
| AR071792A1 (es) | Antagonistas nitrogenados del receptor de glucagon, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de la diabetes tipo ii y afecciones relacionadas. | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
| PE20050951A1 (es) | Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas | |
| AR073574A1 (es) | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| AR077849A2 (es) | Compuestos y composiciones como inhibidores de proteina quinasa | |
| AR056214A1 (es) | Inhibidores de la proteina que activa la 5- lipooxigenasa (flap) | |
| AR070255A1 (es) | Derivados de urea de tetrahidroquinoxalina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la modulacion de la actividad de 11-beta hd1 (hidroxiesteroide deshidrogenasa de tipo 1) | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| AR041250A1 (es) | Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa | |
| AR084730A1 (es) | Ligandos heterociclicos nitrogenados de receptores sigma utiles para el tratamiento de dolor por cancer de huesos | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR067945A1 (es) | Pirimidinas biciclicas fusionadas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |